SFDA Reports 82% Rise in Licensed Factories, Warehouses

The Saudi Food and Drug Authority (SFDA) has reported a record 82% increase in the number of licensed factories and warehouses during 2024 compared with the previous year, according to an official announcement carried by the Saudi Press Agency (SPA). The figures, released from Riyadh, cover the food, pharmaceutical, cosmetics, medical devices, and animal feed sectors, and mark one of the strongest single-year expansions in the Kingdom’s regulated industrial and logistics footprint to date.

The scale of the increase is significant for a regulatory body whose approvals determine which products may be manufactured, stored, and distributed inside Saudi Arabia. In practical terms, the 82% growth means hundreds of additional facilities are now operating under SFDA oversight, strengthening the national supply chain at a time when the Kingdom is pursuing food and drug security as core national priorities. Could any single regulatory reform deliver results this broad across so many industries at once? The SFDA attributes the outcome to a deliberate programme of procedural redesign and investor enablement, carried out in coordination with other government entities, rather than to any one sector’s expansion alone.

Context and Background

How did the SFDA move from routine licensing to a record-setting year? According to the authority, the surge followed a sustained effort to develop the regulatory system and empower investors through a plan containing several initiatives. Central to that plan is the re-engineering of licensing procedures, alongside complementary initiatives designed to stimulate industries and localise production. These measures were implemented in collaboration with various relevant government entities, reflecting the whole-of-government approach that has characterised Saudi regulatory reform in recent years.

The SFDA is the national body responsible for regulating food, drugs, medical devices, cosmetics, and feed, and its licensing decisions shape how quickly businesses can enter the Saudi market. For international manufacturers and investors, the speed and predictability of that process are decisive commercial factors. A regulatory system that shortens approval timelines while maintaining safety standards lowers the cost of market entry and reduces uncertainty for companies weighing whether to build local capacity. That is why the licensing figures are treated as an economic indicator, not merely an administrative statistic.

Why does the timing matter? The 2024 results arrive as Saudi Arabia accelerates industrial diversification under Vision 2030, with an emphasis on domestic manufacturing, resilient supply chains, and reduced reliance on imports in sensitive categories such as food and medicine. A regulatory authority that can process a far larger volume of licences is an enabling institution for that wider national effort, translating policy ambition into operating factories and warehouses on the ground.

Key Details

What do the sector-by-sector numbers actually show? In the food sector, licences were issued for 693 factories and 3,857 warehouses in 2024, making food by far the largest category by both measures. In the pharmaceutical sector, eight factories and 565 warehouses obtained licences. The cosmetics sector recorded 42 factories and 857 warehouses, while the medical devices sector saw 24 factories and 1,405 warehouses licensed. The feed sector accounted for 29 factories and 270 warehouses, and the SFDA additionally licensed nine private laboratories.

The distribution of these approvals is instructive. Warehousing licences vastly outnumber factory licences across every sector, which points to the growing importance of storage, distribution, and cold-chain infrastructure in the Saudi market. For food and medical devices in particular, warehouse capacity is the connective tissue between ports, factories, and consumers. The relatively small number of pharmaceutical factories licensed in the year underscores that drug manufacturing is a longer-cycle, capital-intensive activity, even as the Kingdom continues to build domestic pharmaceutical capability.

The licensing of nine private laboratories adds another dimension, expanding the testing and quality-assurance capacity available to the private sector. Together, these approvals represent a substantial addition to the Kingdom’s regulated infrastructure. Is it any wonder that investors are watching the SFDA’s approval pipeline as a barometer of market openness? Each licence represents a business that has chosen to establish or expand a physical presence in Saudi Arabia, and the aggregate figure suggests that choice is being made far more frequently than a year earlier.

Regulatory Reform and Investor Enablement

What exactly changed inside the licensing process? The SFDA describes a plan featuring several initiatives, foremost among them the re-engineering of licensing procedures. In practice, this means simplifying steps, reducing duplication, and aligning requirements across the entities that touch a single application. When several government bodies are involved in approving a facility, delays compound; streamlining that chain is one of the most effective ways to increase the number of licences issued without lowering standards.

The authority also points to initiatives aimed at stimulating industries and localising production, implemented with relevant government partners. Localisation is a recurring theme in Saudi industrial policy: the goal is to move from importing finished goods to manufacturing them domestically, capturing more of the value chain and creating skilled employment. Regulatory reform and localisation incentives reinforce one another, because a faster licence is of little use if the underlying business case for local production is weak, and vice versa.

For international companies, the practical effect is a more navigable entry process. Firms that previously weighed the administrative burden of establishing a Saudi facility against the benefits of market access now face a different calculus. The 82% growth suggests that many have concluded the balance has shifted in favour of building locally. Does a simpler licence process sound like a minor technical detail? For a manufacturer deciding where to place a factory or a distribution hub, it is often the deciding factor.

International and Regional Impact

How does this development register beyond Saudi borders? The Kingdom is the largest economy in the Middle East and a major importer of food, pharmaceuticals, and medical equipment, so changes in its licensing regime ripple through regional and global supply chains. More licensed warehouses mean more capacity to store and distribute imported and locally produced goods, which can improve reliability for trading partners and reduce bottlenecks at ports and distribution centres.

Regional neighbours and international investors also read these figures as a signal about the broader investment climate. Saudi Arabia has been courting foreign direct investment across manufacturing, logistics, and healthcare, and regulatory predictability is a core part of that pitch. A record year for SFDA licences supports the narrative that the Kingdom is removing friction for businesses that want to operate inside its market, complementing larger initiatives such as special economic zones and industrial cities.

For global pharmaceutical and medical device companies, the licensed warehouses and laboratories represent the physical infrastructure through which their products reach Saudi patients and consumers. Expanded local storage and testing capacity can shorten lead times, improve traceability, and support quality assurance. In food, the numbers speak to a system building depth behind its imports, which matters for a country that relies on trade for a significant share of its nutritional needs.

Economic and Strategic Significance

Why should economists pay attention to licensing data? Licensed factories and warehouses are leading indicators of real economic activity. A factory licence precedes construction, hiring, and production; a warehouse licence precedes inventory flows and distribution employment. When the stock of licensed facilities grows by 82% in a single year, it implies a pipeline of investment that will show up in industrial output, logistics activity, and employment over the coming quarters.

The sectoral mix also carries strategic weight. Food and medicine are security-sensitive categories, and the Kingdom has made clear that it intends to strengthen domestic capacity in both. The 693 food factories licensed in 2024 and the 565 pharmaceutical warehouses point to a supply chain being deliberately thickened. Medical devices, cosmetics, and feed round out an ecosystem that supports public health, consumer markets, and livestock production respectively.

There is a commercial dimension as well. Warehouses and factories generate demand for construction, utilities, refrigeration, transport, and digital systems, spreading the benefits of each licence across multiple industries. The nine private laboratories add high-value testing services that can serve both regulators and businesses. Taken together, the 2024 licensing record is best understood not as an isolated administrative achievement but as an input into the Kingdom’s wider economic expansion.

Vision 2030 Alignment

How does a licensing surge connect to Saudi Arabia’s long-term national plan? Vision 2030 aims to diversify the economy, localise production, strengthen supply-chain resilience, and improve the business environment for domestic and international investors. The SFDA’s regulatory reforms and its collaboration with other government entities sit squarely within that framework, converting policy goals into approvals that businesses can act on.

The record 82% growth in licensed factories and warehouses in 2024 demonstrates that the enabling institutions of the Saudi state are scaling up alongside the Kingdom’s larger ambitions. For international readers, the message is that Saudi Arabia is not only announcing industrial and health-security targets but also building the regulatory machinery to deliver them. As Vision 2030 progresses, the SFDA’s licensing pipeline will remain a useful measure of how quickly the Kingdom’s manufacturing and logistics base is deepening, and how effectively reform is reaching the businesses that power it.

20 Questions

Q1. What did the Saudi Food and Drug Authority announce?

A1. The SFDA reported a record 82% increase in licensed factories and warehouses in 2024 compared with 2023, according to the Saudi Press Agency, covering the food, pharmaceutical, cosmetics, medical devices, and feed sectors.

Q2. What drove the 82% increase in licences?

A2. The SFDA attributed the growth to development of the regulatory system and a plan of initiatives that empower investors, most notably the re-engineering of licensing procedures and measures to stimulate industries and localise production.

Q3. How many food factories were licensed in 2024?

A3. Licences were issued for 693 food factories in 2024, making the food sector the largest category by factory approvals among all sectors regulated by the SFDA during the year.

Q4. How many food warehouses received licences?

A4. The SFDA licensed 3,857 food warehouses in 2024, the highest warehouse figure of any sector and a major addition to the Kingdom’s food storage and distribution capacity.

Q5. What were the pharmaceutical sector licensing figures?

A5. In the pharmaceutical sector, eight factories and 565 warehouses obtained licences in 2024, reflecting continued but capital-intensive growth in domestic drug manufacturing and storage capacity.

Q6. How many cosmetics factories and warehouses were licensed?

A6. The cosmetics sector recorded 42 licensed factories and 857 licensed warehouses in 2024, supporting a consumer market that continues to expand across the Kingdom.

Q7. What did the medical devices sector record?

A7. The medical devices sector saw 24 factories and 1,405 warehouses licensed in 2024, strengthening the infrastructure through which medical equipment reaches hospitals, clinics, and patients in Saudi Arabia.

Q8. What were the feed sector figures?

A8. The feed sector accounted for 29 licensed factories and 270 licensed warehouses in 2024, supporting livestock production and the agricultural supply chain that depends on reliable animal feed.

Q9. How many private laboratories were licensed?

A9. The SFDA licensed nine private laboratories in 2024, expanding testing and quality-assurance capacity available to businesses and complementing the authority’s own oversight activities.

Q10. Which government entities collaborated on the licensing initiatives?

A10. The SFDA said the initiatives were implemented in collaboration with various relevant government entities, reflecting the coordinated, whole-of-government approach that supports Saudi industrial and regulatory reform.

Q11. Why is the re-engineering of licensing procedures important?

A11. Re-engineering reduces duplication and shortens approval timelines without lowering safety standards, making it faster and more predictable for investors to establish factories, warehouses, and laboratories in Saudi Arabia.

Q12. What does localising production mean in this context?

A12. Localising production means manufacturing more goods inside Saudi Arabia rather than importing finished products, capturing more value domestically, creating skilled jobs, and strengthening supply-chain resilience in sensitive categories.

Q13. Why are warehouses so important to the Saudi market?

A13. Warehouses connect ports, factories, and consumers, and are essential for food, pharmaceutical, and medical device distribution. Their growth signals expanding logistics capacity behind the Kingdom’s imports and domestic output.

Q14. How does this relate to food and drug security?

A14. More licensed food factories and pharmaceutical warehouses increase domestic capacity to produce, store, and distribute essential goods, reducing reliance on imports and strengthening national resilience in security-sensitive categories.

Q15. What does the record mean for international investors?

A15. It signals a more navigable and predictable entry process, encouraging foreign manufacturers and logistics firms to establish or expand facilities in Saudi Arabia as part of their regional market strategies.

Q16. How does the licensing growth affect regional supply chains?

A16. As the largest Middle East economy, Saudi Arabia’s expanded storage and manufacturing capacity can improve reliability for trading partners, reduce port bottlenecks, and support distribution across the wider region.

Q17. Are licensed facilities an economic indicator?

A17. Yes. Factory and warehouse licences precede construction, hiring, production, and inventory flows, so a large increase implies a pipeline of investment that will appear in output and employment over time.

Q18. Which sectors are considered security-sensitive?

A18. Food and pharmaceuticals are generally treated as security-sensitive because they affect public health and daily needs, which is why domestic capacity in both is a strategic priority for the Kingdom.

Q19. How does this support Vision 2030?

A19. Vision 2030 seeks economic diversification, localised production, and a stronger business environment. The SFDA’s regulatory reforms and record licensing output translate those goals into approvals that businesses can act on.

Q20. What can readers expect next from the SFDA?

A20. Continued implementation of licensing and industrial-stimulation initiatives is expected, with the authority’s approval pipeline remaining a useful measure of how quickly Saudi Arabia’s manufacturing and logistics base continues to deepen.

---